This is not the most recent version of the article. View current version (15 NOV 2016)

Intervention Review

You have free access to this content

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome

  1. Richard AC Hughes1,*,
  2. Jane Pritchard2,
  3. Robert DM Hadden3

Editorial Group: Cochrane Neuromuscular Group

Published Online: 28 FEB 2013

Assessed as up-to-date: 28 AUG 2012

DOI: 10.1002/14651858.CD008630.pub3


How to Cite

Hughes RAC, Pritchard J, Hadden RDM. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD008630. DOI: 10.1002/14651858.CD008630.pub3.

Author Information

  1. 1

    National Hospital for Neurology and Neurosurgery, MRC Centre for Neuromuscular Diseases, London, UK

  2. 2

    Charing Cross Hospital, Neuromuscular Unit 3 North, London, UK

  3. 3

    King's College Hospital, Department of Neurology, London, UK

*Richard AC Hughes, MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, PO Box 114, Queen Square, London, WC1N 3BG, UK. rhughes11@btinternet.com.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 28 FEB 2013

SEARCH

This is not the most recent version of the article. View current version (15 NOV 2016)

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Bensa 2000 {published and unpublished data}
Pritchard 2003 {published data only}
  • Pritchard J, Gray IA, Hughes RAC, Idrissova ZR, Lecky BRF, Swan AV, et al. A pilot randomised, double-blind, placebo-controlled exploratory safety study of the use of interferon-beta 1a in the treatment of Guillain-Barré syndrome. Journal of the Peripheral Nervous System 2003;8(Suppl 1):52.
  • Pritchard J, Gray IA, Idrissova ZR, Lecky BR, Sutton IJ, Swan AV, et al. A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome. Neurology 2003;61(9):1282-4. [PUBMED: 14610140]
Wollinsky 2001 {published data only}
  • Wollinsky KH, Hülser PJ, Brinkmeier H, Aulkemeyer P, Bössenecker W, Huber-Hartmann KH, et al. CSF filtration is an effective treatment of Guillain-Barré syndrome: a randomized clinical trial. Neurology 2001;57(5):774-80. [PUBMED: 11552002]
Zhang 2000 {published data only}
  • Zhang X, Xia J, Ye H. Effect of Tripterygium polyglycoside on interleukin-6 in patients with Guillain-Barre syndrome. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi/Chinese Journal of Integrated Traditional & Western Medicine/Zhongguo Zhong Xi Yi Jie He Xue Hui, Zhongguo Zhong Yi Yan Jiu Yuan Zhu Ban 2000;20(5):332-4. [PUBMED: 11789240]

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Ahuja 1980 {published data only}
  • Ahuja GK, Mohandas S, Virani V. Cyclophosphamide in Landry-Guillain-Barré syndrome. Acta Neurologica 1980;2(3):186-90. [PUBMED: 7415884]
Bos Eyssen 2011 {published data only}
  • Bos Eyssen ME, van Doorn PA, Jacobs BC, Steyerberg EW, van der Voort PH, Zandstra DF, et al. Selective digestive tract decontamination decreases time on ventilator in Guillain-Barre syndrome. Neurocritical Care 2011;15(1):128-33.
Colin-Jones 1965 {published data only}
  • Colin-Jones DG, Heathfield KWG. 6-mercaptopurine in polyradiculoneuropathy. Lancet 1965;2:739.
Créange 1998 {published data only}
De Grandis 1995 {published data only}
  • De Grandis D, Santoro L, Di Benedetto P. L-acetylcarnitine in the treatment of patients with peripheral neuropathies: a short term, double-blind clinical study of 426 patients. Clinical Drug Investigation 1995;10(6):317-22.
Feasby 1991 {published data only}
Francesconi 1972 {published data only}
  • Francesconi G, Mellina S. Clinical trial of a new coenzymatic complex (Ro 8-0743-4). [Italian]. Clinica Terapeutica 1972;62(3):253-71. [PUBMED: 4507658]
Gamstorp 1966 {published data only}
  • Gamstorp I, Aronsson S, Lindquist B. Mercaptopurine in polyradiculoneuropathy. Lancet 1966;i:99-100.
Garssen 2007 {published and unpublished data}
  • Garssen MP, van Koningsveld R, van Doorn PA, Merkies IS, Scheltens-de BM, van Leusden JA, et al. Treatment of Guillain-Barré syndrome with mycophenolate mofetil: a pilot study. Journal of Neurology, Neurosurgery & Psychiatry 2007;78(9):1012-3. [PUBMED: 17702789]
  • Garssen MPJ, van Koningsveld R, van Doorn PA. Treatment of Guillain-Barré syndrome with intravenous immunoglobulins and methylprednisolone combined with mycophenolate (CELLCEPT®) - a pilot study. Journal of the Peripheral Nervous System 2005;10:S24.
Gorbunov 1995 {published data only}
  • Gorbunov FE, Vinnikov AA, Strelkova NI, Krupennikov AI. The use of pulsed and continuous UHF electrical fields in the rehabilitation of patients with the Guillain-Barre syndrome and other peripheral myelinopathies. [Russian]. Zhurnal Nevrologii i Psikhiatrii Imeni S S Korsakova 1995;95(5):22-6.
Hammond 1993 {published data only}
  • Hammond JM, Potgieter PD. Neurologic disease requiring long-term ventilation. The role of selective decontamination of the digestive tract in preventing nosocomial infection. Chest 1993;104(2):547-51.
Hilz 1992 {published data only}
Huang L 1998 {published data only}
Huang X 1998 {published data only}
  • Huang XM, Yuan GG. Ultraviolet radiation and oxygen enrichment self-blood transfusion therapy for Guillain-Barre syndrome. Chinese Journal of Neurology 1998;31:123.
Husstedt 1993 {published data only}
  • Husstedt IW, Thumler R, Roder R, Dreyer M, Leopold W, Scheller W. Treatment of polyneuropathies. Investigations on efficacy of ginkgo biloba extract EGb 761 in patients with polyneuropathy. [German]. Zeitschrift fur Allgemeinmedizin 1993;69(26):714-17.
Li 1998 {published data only}
  • Li AY, Wang HX, Liu QX, Sun JX, Lu SJ, Yang Z. Ultraviolet rays for Guillain-Barré syndrome. Chinese Journal of Physical Therapy 1998;21:178-9.
Meythaler 2000 {published data only}
  • Meythaler JM, Guin RS, Johnson A, Brunner RM. The safety and efficacy of 4-aminopyridine for motor weakness due to Guillain-Barré syndrome: a double-blind cross-over phase I drug trial. Archives of Physical Medicine & Rehabilitation 2000;81:1293.
Ostronoff 2008 {published data only}
  • Ostronoff F, Perales MA, Stubblefield MD, Hsu KC, Ostronoff F, Perales MA, et al. Rituximab-responsive Guillain-Barre syndrome following allogeneic hematopoietic SCT. Bone Marrow Transplantation 2008;42(1):71-2.
Palmer 1965 {published data only}
Palmer 1966 {published data only}
Rosen 1976 {published data only}
Schaller 2001 {published data only}
  • Schaller B, Radziwill AJ, Steck AJ. Successful treatment of Guillain-Barré syndrome with combined administration of interferon-beta-1a and intravenous immunoglobulin. European Neurology 2001;46(3):167-8. [PUBMED: 11598343]
Wang 2006 {published data only}
  • Wang H, Li M, Wang F, Dong G, Wang J, Zhang E. Electroacupuncture at shu-points of the five zang-organs for treatment of the flaccidity syndrome. Chinese Journal of Clinical Rehabilitation 2006;10(3):124-6.
Warembourg 1967 {published data only}
  • Warembourg H, Jaillard J. Clinical trial of "F.E.V. 300". Apropos of 300 cases. [French]. Lille Medical 1967;12(7 (Suppl)):746-8. [PUBMED: 5615429]
Yuill 1970 {published data only}
Zagar 1995 {published data only}
  • Zagar M. Treatment of Guillain-Barré syndrome. Lijecnicki Vjesnik 1995;117(9-10):246-9. [PUBMED: 8643618]

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Asbury 1990
Bernsen 1999
  • Bernsen RA, de Jager AE, Schmitz PI, van der Meché FG. Residual physical outcome and daily living 3 to 6 years after Guillain-Barré syndrome. Neurology 1999;53(2):409-10. [PUBMED: 10430437]
Brinkmeier 1992
  • Brinkmeier H, Wollinsky KH, Hulser PJ, Seewald MJ, Mehrkens H, Kornhuber HH, et al. The acute paralysis in Guillain-Barré syndrome is related to a Na+ channel blocking factor in the cerebrospinal fluid. Pflugers Archiv: European Journal of Physiology 1992;421:552-7. [PUBMED: 1331974]
Bussman 2007
  • Bussman JB, Garssen MP, van Doorn PA, Stam HJ. Analysing the favourable effects of physical exercise: relationships between physical fitness, fatigue and functioning in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. Journal of Rehabilitation Medicine 2007;39(2):121-5. [PUBMED: 17351693]
Cummins 2003
D'Amico 2009
Demir 2008
  • Demir SO, Köseoğlu F. Factors associated with health-related quality of life in patients with severe Guillain-Barré syndrome. Disability and Rehabilitation 2008;30(8):593-9. [PUBMED: 17852306]
Feasby 2001
Goldbach-Mansky 2009
  • Goldbach-Mansky R, Wilson M, Fleischmann R, Olsen N, Silverfield J, Kempf P, et al. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Annals of Internal Medicine 2009;151(4):229-40. [PUBMED: 19687490]
Hadden 1998
  • Hadden RDM, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Annals of Neurology 1998;44(5):780-8. [PUBMED: 9818934]
Higgins 2008
  • Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley & Sons, 2008.
Hughes 1978
Hughes 1990
  • Hughes RAC. Guillain-Barré Syndrome. Heidelberg: Springer-Verlag, 1990.
Hughes 2005
Hughes 2007
  • Hughes RA, Swan AV, Raphaël JC, Annane D, van Koningsveld R, van Doorn PA. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 2007;130(Pt 9):2245-57. [PUBMED: 17337484]
Hughes 2010
Hughes 2010b
  • Hughes RA, Gorson KC, Cros D, Griffin J, Pollard J, Vallat JM, et al. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2010;74(8):651-7. [PUBMED: 20177118]
Hughes 2012
  • Hughes RAC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2012;7:CD002063. [DOI: 10.1002/14651858.CD002063.pub5]
Hughes 2012a
  • Hughes RA, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2012;8:CD001446. [DOI: 10.1002/14651858.CD001446.pub4]
Jaso 2010
  • Jaso R, Sierra M, Calleja J, Valero C, Pascual J. Guillain-Barre syndrome after rituximab in a patient with idiopathic thombocytopenic purpura: a causal association?. Journal of Neurology 2010;257(3):488-9. [PUBMED: 20229293]
Khiani 2008
  • Khiani V, Kelly T, Shibli A, Jensen D, Mohanty SR. Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon alpha 2a therapy for chronic hepatitis C virus infection. World Journal of Gastroenterology 2008;14(2):318-21. [PUBMED: 18186575]
Linker 2010
  • Linker RA, Lee DH, Demir S, Wiese S, Kruse N, Siglienti I, et al. Functional role of brain derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain 2010;133(8):2248-63. [PUBMED: 20826436]
Ludolph 2010
  • Ludolph A (Department of Neurology, University of Ulm). Email to Prof RAC Hughes dated 1st September 2010. Located at Cochrane Neuromuscular Disease Group Editorial Base.
Mahdi-Rogers 2010
Mak 2009
  • Mak A, Cheak AA, Tan JY, Su HC, Ho RC, Lau CS. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology (Oxford) 2009;48(8):944-52. [PUBMED: 19494179]
Martin 2009
Merkies 1999
  • Merkies IS, Schmitz PI, Samijn JP, van der Meché FG, van Doorn PA. Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 1999;53(8):1648-54. [PUBMED: 10563607]
Otto 2005
  • Otto F, Kieseier BC, Gortz P, Hartung HP, Siebler M. The pentapeptide QYNAD does not inhibit neuronal network activity. Canadian Journal of Neurological Sciences 2005;32(3):344-8. [PUBMED: 16225177]
Plasma 1997
  • Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997;349(9047):225-30. [PUBMED: 9014908]
Raphael 2012
  • Raphael JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2012;7:CD001798.
Ravaglia 2008
  • Ravaglia S, Corso A, Piccolo G, Lozza A, Alfonsi E, Mangiacavalli S, et al. Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clinical Neurophysiology 2008;119(11):2507-12. [PUBMED: 18829381]
Rees 1998
  • Rees JH, Thompson RD, Smeeton NC, Hughes RA. Epidemiological study of Guillain-Barré syndrome in south east England. Journal of Neurology, Neurosurgery and Psychiatry 1998;64(1):74-7. [PUBMED: 9436731]
RevMan 2008 [Computer program]
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
Rice 2001
  • Rice GP, Incorvaia B, Munari L, Ebers G, Polman C, D'Amico R, et al. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD002002]
Roche
  • Roche Products Limited. Cellcept Summary of Product Characteristics last updated on the eMC: 27/10/2009. Electronic Medicines Compendium (eMC) YR:2010.
Sanders 2008
Shin 2006
Turatti 2010
van Koningsveld 2004
  • van Koningsveld R, Schmitz PI, van der Meché FG, Visser LH, Meulstee J, van Doorn PA for the Dutch GBS study group. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet 2004;363:192-6.
Victor 2008
  • Victor F, Menon K, Latkowski JA, Fernandez-Obregon A, Strober BE, Victor F, et al. Efalizumab-associated Guillain-Barré syndrome. Archives of Dermatology 2008;144(10):1396-7. [PUBMED: 18936412]
Wollinsky 1995
  • Wollinsky KH, Hülser PJ, Brinkmeier H, Mehrkens H-H, Kornhuber HH, Rüdel R. Clinical experiences with CSF filtration in Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy and multiple sclerosis [Klinische Erfahrungen mit der CSF-Filtration bei Guillain-Barré Syndrom, chronisch inflammatorischer demyelinisierender Polyneuropathie und multipler Sklerose]. Neuropsychiatrie 1995;9:95-9.
Yuki 2012
Zhang 2008

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Hughes 2010c
  • Hughes RAC, Pritchard J, Hadden RDM. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain Barré syndrome. Cochrane Database of Systematic Reviews 2010, Issue 8. [DOI: 10.1002/14651858.CD008630]
Hughes 2011